Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 37, Issue 2, Pages 343-355Publisher
IOS PRESS
DOI: 10.3233/JAD-130578
Keywords
Alzheimer's disease; A beta PP; ASBI; galangin; pro-drug; rutin
Categories
Funding
- National Institute of Health [AG034427]
- Ellen and Douglas Rosenberg Foundation
Ask authors/readers for more resources
A systematic approach was used to identify A beta PP-selective BACE inhibitors (ASBI) and to evaluate their in vivo ability to modulate A beta PP processing selectively. We identified a bioflavonoid nutritional supplement as a molecular lead that acts as an ASBI in cell models, and show that increasing brain levels of this bioflavonoid through a pro-drug approach leads to reduction of A beta(42) in an Alzheimer's disease mouse model. ASBIs represent a novel class of candidate therapeutic agents for Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available